IMR Press / JOMH / Special Issues / 1336850851644227584

Therapy and prognosis of metastatic prostate cancer

Submission deadline: 31 August 2021
Special Issue Editor
  • Kullmann Tamás, PhD
    Department of Oncology, Petz Aladár Hospital, Győr, Hungary
    Interests: Infections and malignancies of the urinary tract; Diagnosis of “fever of unknown origin”; Oncologic emergencies; Pain relief for cancer patients
Special Issue Information

Dear Colleagues,

Please let me invite you to contribute to the preparation and later to favour a mindful lecture of this speciel issue of the Journal of Men’s Health dedicated to metastatic prostate cancer.

Although being a leading cause of cancer death, metastatic prostate cancer, compared to other cancer types, is any longer necesserily a life threatening condition. Thanks to recent pharmaceutical developments, several lines of anti-hormonal and cytostatic treatments may provide long years of disease control.

We would like to focus in this special issue to the diagnostic challenges, to the proper use of innovative therapies and to the patients’ perspectives open with the improved prognosis. Differentiating between localised and generalised disease remains problematic even with the best imaging techniques. Sequencing and maintenance of novel drugs are being debated. The men’s own evaluation of the quality of their prolonged life is maybe not enough taken into account.

This special issue offers an opportunity to address the following but other topics:

- Diagnosis and treatment of oligometastatic disease

- Diagnosis and treatment of micrometastatic disease

- Diagnosis and treatment of neuroendocrin cancer of the prostate

- Optimal selection of systemic therapies

- Optimal maintenance of second line antiandrogenic therapies

- Optimal comedication of androgen synthesis inhibitors

- Optimal dosing of bisphosphonates

- Quality of life of patients with metastatic prostate cancer

Let’s share our experience to the better care of the patients of all of us.

Kullmann Tamás

Guest Editor

Prostate cancer
Metastatic prostate cancer
Quality of life
Oligometastatic disease
Micrometastatic disease
Androgen synthesis inhibitors
Second line antiandrogenic therapies
Manuscript Submission Information

Manuscripts should be submitted via our online editorial system at by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website. Research articles, reviews as well as short communications are preferred. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office to announce on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. The Article Processing Charge (APC) in this open access journal is 1500 USD. Submitted manuscripts should be well formatted in good English.

Published Paper (12 Papers)
Back to top